Subcutaneous (SC) Lenacapavir (LEN)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Pre-Exposure Prophylaxis of HIV Infection

Drug Information

Target Indication

Pre-Exposure Prophylaxis of HIV Infection

Clinical Trial

Last updated: 1/7/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

GILD

Gilead Sciences, Inc.

Related Pipeline

Head and Neck Squamous Cell Carcinoma

HIV Prevention

Myelodysplastic Syndrome

Rheumatoid Arthritis

Acquired Immunodeficiency Syndrome

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts